Back to top

Image: Bigstock

Compared to Estimates, Skyward (SKWD) Q1 Earnings: A Look at Key Metrics

Read MoreHide Full Article

Skyward Specialty Insurance (SKWD - Free Report) reported $475.87 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 44.9%. EPS of $1.25 for the same period compares to $0.90 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $398.43 million, representing a surprise of +19.44%. The company delivered an EPS surprise of +19.05%, with the consensus EPS estimate being $1.05.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Skyward performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Expense ratio: 28.4% versus 28.5% estimated by four analysts on average.
  • Loss ratio: 61.1% compared to the 62.3% average estimate based on four analysts.
  • Combined ratio: 89.5% versus the four-analyst average estimate of 90.8%.
  • Revenues- Net investment income: $27.06 million versus the four-analyst average estimate of $24.09 million. The reported number represents a year-over-year change of +40%.
  • Revenues- Commission and fee income: $1.53 million versus $2.08 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -22.7% change.
  • Revenues- Net earned premiums: $434.01 million versus the four-analyst average estimate of $354.88 million. The reported number represents a year-over-year change of +44.5%.

View all Key Company Metrics for Skyward here>>>

Shares of Skyward have returned -0.1% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks' 7 Best Strong Buy Stocks (New Research Report)

Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in